Who owns Spero Therapeutics, Inc. (PERWQ)? Elite investor 13F holders
2 tracked elite investors reported holding Spero Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, Alphabet. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | SPERO THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 2094868.00 USD | 947904.000000 | Shares | reduce | Original filing |
| Alphabet | SPERO THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 1966854.00 USD | 889979.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.